Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PTGIR | P43119 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657784 | 0.96 | LMNA (0.55) | LMNASMN1; SMN2PTGIRMEN1KMT2A | |
| SCHEMBL5659767 | 0.92 | PTGIR (0.57) | LMNASMN1; SMN2PTGIRADRA2AADRA2B | |
| SCHEMBL5656401 | 0.92 | PTGIR (0.61) | LMNASMN1; SMN2PTGIRMEN1KMT2A | |
| SCHEMBL5656110 | 0.91 | PTGIR (0.53) | LMNASMN1; SMN2PTGIRADRA2AADRA2B | |
| SCHEMBL5659141 | 0.89 | ADRA2A (0.54) | LMNASMN1; SMN2PTGIRADRA2AADRA2B | |
| SCHEMBL5656473 | 0.88 | PTGIR (0.71) | SMN1; SMN2PTGIRMEN1KMT2AADRA2A | |
| SCHEMBL5656724 | 0.87 | PTGIR (0.53) | LMNAPTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL5656678 | 0.86 | ADRA2A (0.56) | PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL5658627 | 0.86 | ADRA2A (0.59) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| SCHEMBL5659545 | 0.86 | PTGIR (0.52) | LMNAPTGIRADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-6998414-B2 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-02-14 | — | — | US | disclosed |
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | INSR, INSRR, GIPR | LMNA 4822/4885SMN1; SMN2 4654/4885PTGIR 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.